Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: Clues but no clear answers

Autophagy

Volumn 4, Issue 5, 2008, Pages 707-709

  Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Akt; Apoptosis; Autophagy; Cyclin D; Everolimus; Temsirolimus

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; TEMSIROLIMUS;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; MANTLE CELL LYMPHOMA;

MAMMALIA;

EID: 48249090836     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.6232     Document Type: Article

References (21)

1. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347-56.
2. Johnston PB, Ansell SM, Colgan JP, et al. Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma. ASCO Meeting Abstracts 2007; 25:8055.
3. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res 2007; 13:7280-7.
4. Yazbeck VY, Buglio D, Georgakis GV, et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 2008; 36:443-50.
5. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007; 21:333-9.
6. Dal Col J, Zancai P, Terrin L, et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008.
7. Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 2005; 90:1433-4.
8. Baehrecke EH. Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol 2005; 6:505-10.
9. Kabeya Y, Mizushima N, Ueno T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. Embo J 2000; 19:5720-8.
10. Pattingre S, Espert L, Biard Piechaczyk M, Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie 2008; 90:313-23.
11. WAF1/CIP1 in apoptosis and autophagy. J Biol Chem 2007.
12. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22.
13. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 2005; 12:1509-18.
14. Hait WN, Jin S, Yang JM. A Matter of Life or Death (or Both): Understanding Autophagy in Cancer. Clin Cancer Res 2006; 12:1961-5.
15. Johnston PB, Ansell SM, Colgan JP, et al. mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001). Blood (ASH Annual Meeting Abstracts) 2007; 110:2555.
16. Smith SM, Pro B, Smith S, et al. Molecular Inhibition of mTOR with Temsirolimus (TORISELTM, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium. Blood (ASH Annual Meeting Abstracts) 2006; 108:2483.
17. 1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006; 132:503-11.
18. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006; 169:2171-80.
19. Klionsky DJ, Cuervo AM, Seglen PO. Methods for monitoring autophagy from yeast to human. Autophagy 2007; 3:181-206.
20. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007; 13:7271-9.
21. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117:326-36.